A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A
Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid leukemia patients after a higher rate of deaths was seen.
You may also be interested in...
The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.